Butyric Acid Increases the Therapeutic Effect of EHLJ7 on Ulcerative Colitis by Inhibiting JAK2/STAT3/SOCS1 Signaling Pathway

Ulcerative colitis (UC) is a refractory chronic disease characterized by bloody diarrhea and mucosal or submucosal ulcers. There is an urgent need of new drugs for the treatment of ulcerative colitis. EHLJ7 is a quaternary coptisine derivative. Herein, we explored the therapeutic effect of EHLJ7 on...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 10; p. 1553
Main Authors Tang, Xiaonan, Li, Xiang, Wang, Yufei, Zhang, ZhiHui, Deng, AnJun, Wang, WenJie, Zhang, Haijing, Qin, Hailin, Wu, LianQiu
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 22.01.2020
Subjects
butyric acid
JAK2
Pharmacology
SOCS1
STAT3
ulcerative colitis
butyric acid
ulcerative colitis
SOCS1
JAK2
STAT3
Online AccessGet full text

Cover

More Information
Summary:Ulcerative colitis (UC) is a refractory chronic disease characterized by bloody diarrhea and mucosal or submucosal ulcers. There is an urgent need of new drugs for the treatment of ulcerative colitis. EHLJ7 is a quaternary coptisine derivative. Herein, we explored the therapeutic effect of EHLJ7 on dextran sodium sulfate (DSS)-induced ulcerative colitis (UC) in mice. Results showed that EHLJ7 have good effects on DSS-induced colitis. EHLJ7 significantly improved symptoms induced by DSS including of weight loss, colon contracture, disease activity index (DAI), inflammatory infiltration, and so on. Furthermore, results showed that EHLJ7 could enhance short-chain fatty acids (SCFAs) production especially butyric acid, suggesting that EHLJ7 could improve the metabolic disorder of intestinal flora to a certain extent. Further study indicated that EHLJ7 could cooperate with butyrate to exert its anti-ulcerative colitis effect by inhibiting the activation of janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/suppressor of cytokine signaling 1 (SOCS1) pathway. Therefore, EHLJ7 has a potential to be developed as a candidate for the treatment of colitis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Joseph Larkin, University of Florida, United States; Ashok Kumar Pandurangan, B.S. Abdur Rahman University, India
Edited by: Luca Antonioli, University of Pisa, Italy
These authors have contributed equally to this work
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.01553